Suppr超能文献

结节性再生性增生:被低估的门静脉高压症病因。

Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.

出版信息

World J Gastroenterol. 2011 Mar 21;17(11):1400-9. doi: 10.3748/wjg.v17.i11.1400.

Abstract

Nodular regenerative hyperplasia (NRH) is a rare liver condition characterized by a widespread benign transformation of the hepatic parenchyma into small regenerative nodules. NRH may lead to the development of non-cirrhotic portal hypertension. There are no published systematic population studies on NRH and our current knowledge is limited to case reports and case series. NRH may develop via autoimmune, hematological, infectious, neoplastic, or drug-related causes. The disease is usually asymptomatic, slowly or non-progressive unless complications of portal hypertension develop. Accurate diagnosis is made by histopathology, which demonstrates diffuse micronodular transformation without fibrous septa. Lack of perinuclear collagen tissue distinguishes NRH from typical regenerative nodules in the cirrhotic liver. While the initial treatment is to address the underlying disease, ultimately the therapy is directed to the management of portal hypertension. The prognosis of NRH depends on both the severity of the underlying illness and the prevention of secondary complications of portal hypertension. In this review we detail the epidemiology, pathogenesis, diagnosis, management, and prognosis of NRH.

摘要

结节性再生性增生 (NRH) 是一种罕见的肝脏疾病,其特征为肝脏实质广泛良性转化为小结节再生。NRH 可能导致非肝硬化性门静脉高压的发展。目前尚无关于 NRH 的系统人群研究,我们的现有知识仅限于病例报告和病例系列。NRH 可能由自身免疫、血液学、感染、肿瘤或药物相关原因引起。该病通常无症状,除非发生门静脉高压的并发症,否则进展缓慢或非进行性。组织病理学可做出准确诊断,其表现为弥漫性微小结节性转化,无纤维间隔。缺乏核周胶原组织可将 NRH 与肝硬化肝脏中的典型再生结节区分开来。虽然初始治疗是针对潜在疾病,但最终的治疗方案是针对门静脉高压的管理。NRH 的预后取决于潜在疾病的严重程度和预防门静脉高压的继发性并发症。在本综述中,我们详细介绍了 NRH 的流行病学、发病机制、诊断、治疗和预后。

相似文献

引用本文的文献

3
Role of mitogens in normal and pathological liver regeneration.有丝分裂原在正常及病理性肝再生中的作用。
Hepatol Commun. 2025 Apr 30;9(5). doi: 10.1097/HC9.0000000000000692. eCollection 2025 May 1.
5
Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer.乳腺癌中新型抗体药物偶联物的毒性及管理策略
Ther Adv Med Oncol. 2025 Mar 24;17:17588359251324889. doi: 10.1177/17588359251324889. eCollection 2025.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验